One of the limitations of this study was that all of the patients entered on the trial had WHO type B2 and B3 thymoma, whereas the molecular features suggest that the PI3K/AKT pathway may be especially important for WHO type A and AB thymoma. The gene discussed is PIK3CA; the disease is thymoma.